Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Open-Label Study Evaluating the Safety and Different Injection Techniques of CCH for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP)

NCT03632993 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT03632993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03632993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Open-Label Study Evaluating the Safety and Different Injection Techniques of CCH for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP)
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 2
Overall status
Completed
Start date
September 18, 2018
Completion date
January 24, 2019
Enrollment
64 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

edematous skin